EurekAlert! -
12 Apr 2014 06:00
(European Association for the Study of the Liver) Results from three Phase III clinical trials evaluating the investigational once-daily fixed-dose combination of the nucleotide analogue polymerase inhibitor sofosbuvir 400mg and the NS5A inhibitor ledipasvir 90mg, with and without ribavirin, for the treatment of genotype 1 chronic hepatitis C virus infection have been presented at the International Liver Congress 2014.
Share this Article